Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cardiac safety of fordadistrogene movaparvovec gene therapy in Duchenne muscular dystrophy: Initial observations from a phase 1b trial

2 Jul 2025

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cardiomyopathy and Myosin Studies
Share to Muscle Physiology and Disorders
Share to Virus-based gene therapy research

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 40583273
DOI: 10.1016/j.ymthe.2025.06.031

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cardiac safety of fordadistrogene movaparvovec gene therapy in Duchenne muscular dystrophy: Initial observations from a phase 1b trialPMID 40583273Read ↗

Consensus recommendations and considerations for the delivery and monitoring of gene therapy in patients with Duchenne muscular dystrophySemantic proximity Read ↗

Progress in Clinical Gene Therapy for Cardiac DisordersSemantic proximity Read ↗

Review of cardiac safety in onasemnogene abeparvovec gene replacement therapy: translation from preclinical to clinical findingsSemantic proximity Read ↗

Delandistrogene Moxeparvovec Gene Therapy in Individuals With Duchenne Muscular Dystrophy: Evidence in FocusSemantic proximity Read ↗

Review of cardiac safety in onasemnogene abeparvovec gene therapy: translation from preclinical to clinical findingsSemantic proximity Read ↗

Food and Drug Administration Lifts Clinical Hold on Pfizer Duchenne Muscular Dystrophy Gene Therapy Linked to Patient DeathSemantic proximity Read ↗

Cardiac cell therapy: Lessons from clinical trialsSemantic proximity Read ↗

Death after High-Dose rAAV9 Gene Therapy in a Patient with Duchenne’s Muscular DystrophySemantic proximity Read ↗

Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trialSemantic proximity Read ↗

After Patient Death, FDA Places Hold on Pfizer Duchenne Muscular Dystrophy Gene Therapy TrialSemantic proximity Read ↗

Evolving Therapeutic Options for the Treatment of Duchenne Muscular DystrophySemantic proximity Read ↗

Steroids in Duchenne muscular dystrophy: from clinical trials to genomic researchSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.